Nkarta (NKTX) Stock Forecast, Price Target & Predictions
NKTX Stock Forecast
Nkarta stock forecast is as follows: an average price target of $21.60 (represents a 811.39% upside from NKTX’s last price of $2.37) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
NKTX Price Target
The average price target for Nkarta (NKTX) is $21.60 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $15.00. This represents a potential 811.39% upside from NKTX's last price of $2.37.
NKTX Analyst Ratings
According to 9 Wall Street analysts, Nkarta's rating consensus is 'Buy'. The analyst rating breakdown for NKTX stock is 1 'Strong Buy' (11.11%), 8 'Buy' (88.89%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Nkarta Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 26, 2024 | Bill Maughan | Canaccord Genuity | $16.00 | $9.61 | 66.58% | 575.11% |
| Mar 22, 2024 | Gil Blum | Needham | $15.00 | $12.98 | 15.56% | 532.91% |
| Mar 22, 2024 | Salim Syed | Mizuho Securities | $25.00 | $8.92 | 180.27% | 954.85% |
| Mar 22, 2024 | Laura Prendergast | Raymond James | $16.00 | $8.92 | 79.37% | 575.11% |
| Apr 26, 2022 | Raymond James | $32.00 | $18.72 | 70.94% | 1250.21% | |
| Apr 26, 2022 | H.C. Wainwright | $36.00 | $18.72 | 92.31% | 1418.99% |
The latest Nkarta stock forecast, released on Mar 26, 2024 by Bill Maughan from Canaccord Genuity, set a price target of $16.00, which represents a 66.58% increase from the stock price at the time of the forecast ($9.61), and a 575.11% increase from NKTX last price ($2.37).
Nkarta Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $18.00 |
| Last Closing Price | $2.37 | $2.37 | $2.37 |
| Upside/Downside | -100.00% | -100.00% | 659.49% |
In the current month, the average price target of Nkarta stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nkarta's last price of $2.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 09, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Aug 14, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 26, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Mar 22, 2024 | Barclays | Buy | Buy | Hold |
| Mar 22, 2024 | Raymond James | Strong Buy | Outperform | Downgrade |
| Oct 17, 2023 | Raymond James | Strong Buy | Upgrade | |
| Mar 17, 2023 | Credit Suisse | Buy | Buy | Hold |
| Dec 22, 2022 | Oppenheimer | Outperform | Perform | Downgrade |
| Dec 05, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 18, 2022 | SVB Leerink | Outperform | Initialise | |
| Apr 26, 2022 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Apr 25, 2022 | Zacks Investment Research | Buy | Upgrade |
Nkarta's last stock rating was published by Rodman & Renshaw on Oct 09, 2024. The company Initialise its NKTX rating from "null" to "Buy".
Nkarta Financial Forecast
Nkarta Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nkarta's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nkarta EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nkarta's previous annual EBITDA (undefined) of $NaN.
Nkarta Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-32.11M | $-31.80M | $-30.99M | $-32.34M | $-29.28M | $-27.04M | $-34.67M |
| High Forecast | $-32.11M | $-31.80M | $-30.99M | $-31.58M | $-26.35M | $-27.04M | $-34.67M |
| Low Forecast | $-32.11M | $-31.80M | $-30.99M | $-33.09M | $-31.47M | $-27.04M | $-34.67M |
| Surprise % | - | - | - | - | - | - | - |
Nkarta's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nkarta SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Nkarta's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NKTX last annual SG&A of $NaN (undefined).
Nkarta EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.44 | $-0.40 | $-0.37 | $-0.47 |
| High Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.43 | $-0.36 | $-0.37 | $-0.47 |
| Low Forecast | $-0.44 | $-0.43 | $-0.42 | $-0.45 | $-0.43 | $-0.37 | $-0.47 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Nkarta's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NKTX previous annual EPS of $NaN (undefined).
Nkarta Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NKTX | Nkarta | $2.27 | $21.60 | 851.54% | Buy |
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |